IV. chemical antigen receptor and application method of bioconcentration coefficient

摘要

p The present application provides single domain antibodies directed to BCMA, and chimeauric antigen receptors (such as monovalent CAR, and multivalent CAR including bi-epithelial CAR) comprising one or more domain antibodies simple anti-BCMA. Genetically modified immune effector cells (such as T lymphocytes) are also provided that comprise the chimeauric antigenic receptors. Pharmaceutical compositions, kits, and methods are also provided to treat cancer. /p